Inventiva S.A. (IVA)
Nasdaq · Healthcare · Biotechnology
$3.48−2.25%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $822M
- 52-week range
- $3.11 – $7.98
- 52-week change
- −35.51%
- EPS (trailing)
- −$0.62
- Analyst rating
- 1.1 Strong buy
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Headquarters: Daix, France · 87 employees · inventivapharma.com